idiopathic pulmonary fibrosis treatment

Oct 10, 2025

Over a decade after launching one of the first treatments for idiopathic pulmonary fibrosis, Boehringer Ingelheim is rejuvenating its presence in the rare lung disease arena with a newly approved therapy. On October 7, the FDA approved JASCAYD, marking the first new IPF treatment in over ten years. The approval fol...

Sep 26, 2022

Idiopathic pulmonary fibrosis (IPF) is a rare, sporadic, and fatal interstitial lung disease. As the morbidity and mortality rates associated with IPF remain high, prompt idiopathic pulmonary fibrosis treatment is critical to safeguard individuals’ lung function, reduce the risk of acute exacerbations, and improve ...